



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/726,024

12/02/2003

Manesh Dixit

141-239A

2662

47888 7590 06/14/2007  
HEDMAN & COSTIGAN P.C.  
1185 AVENUE OF THE AMERICAS  
NEW YORK, NY 10036

EXAMINER

CLAYTOR, DEIRDRE RENEE

ART UNIT

PAPER NUMBER

1617

MAIL DATE

DELIVERY MODE

06/14/2007

PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

**Office Action Summary**

Application No.

10/726,024

Applicant(s)

DIXIT ET AL.

Examiner

Renee Claytor

Art Unit

1617

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 14 May 2007.
- 2a) ☐ This action is FINAL. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1,3-22,24-26 and 28 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1,3-22,24-26 and 28 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- |  |   |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)                                | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)                       | 5) <input type="checkbox"/> Notice of Informal Patent Application                       |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)<br>Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____  |

**DETAILED ACTION**

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 5/14/2007 has been entered.

***Response to Arguments***

Applicant's arguments filed 5/14/2007 have been fully considered but they are not persuasive.

Applicants argue that the Mehta reference fails to disclose or suggest the use of an enteric material to control the release of methylphenidate. The Examiner agrees with this assertion; however, the Mehta reference was never used for teaching an enteric coating polymer. The second paragraph of the Office Action dated 2/15/2007 states that Mehta et al. does not teach enteric coating polymers and the Mulye reference was used to fill this deficiency.

Applicants argue that the Mulye reference teaches that the amount of enteric polymer should not exceed 25% of the coating. Applicants further argue that the Mulye reference fails to provide any working examples that employ methylphenidate. The Examiner notes that Mulye does suggest that the enteric polymer should not exceed 25% of the coating. Please see the new rejection given below to address this issue

Art Unit: 1617

further (Beiman et al.). The Examiner also notes that Mulye does not have working examples that employ methylphenidate; however, the teachings of Mulye are not drawn to a particular compound in their teaching of a controlled release formulation. Mulye teaches that any type of medication, which acts locally in the mouth or systemically, is usable in the controlled release formulation.

### ***Claim Rejections – 35 U.S.C. § 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1, 3-22, 24-26 and 28 are rejected under 35 U.S.C. 103(a) as being unpatentable over Mehta et al. (U.S. Patent 5,837,284) in view of Mulye (U.S. Patent 6,475,493) and Beiman et al. (U.S. Patent 6,312,728).

Mehta et al. teach an improved dosing of methylphenidate hydrochloride whereby two time-separated doses are provided via a single dosage unit, in which a first group of particles provides an immediate dose of methylphenidate in an amount from about 2% to about 99% by weight and a second group of particles provides a second dose of methylphenidate in an amount from about 2% to about 75% with a binder (meeting the limitations of claims 1, 21-22; Col. 1, lines 13-17 and Col. 3, lines 41-43). Mehta et al. further teach a coating that delays the release of the methylphenidate (Col. 4, lines 32-36). The dosage unit is comprised of talc (meeting the limitations of claims

Art Unit: 1617

14 and 15; Col. 8, line 62), plasticizers such as citrates and polyethylene glycols (meeting the limitations of claims 12 and 13; Col. 9, lines 13-14), and hydroxypropyl methylcellulose (meeting the limitations of claims 5-7 and 16; Col. 10, lines 42-50). Mehta et al. further teach that the maximum concentration of the first dose occurs from about 1 hour to about 3 hours after ingestion, which is followed by a period when no drug is released which lasts approximately 2-6 hours, and the second dose is released about 6 hours following administration (meeting the limitations of claims 17, 28-29; Col. 5, lines 37-51 and Fig. 2).

Mehta et al. does not teach a diluent in the core, anti-sticking agents (enumerated in claims 8-9), that the coating is specifically made up of enteric coating polymers, peak blood plasma levels in the immediate release and extended release portions, a maximum plasma concentration up to about 20 ng/ml, and AUC<sub>0-24</sub> up to about 200 ng/ml.

Mulye teaches a coating composition in a controlled release pharmaceutical composition which comprises an enteric polymer (Col. 4, lines 59-62). Active medications that can be used in the composition include methylphenidate (Col. 9, line 42). The compositions contain lactose (meeting the limitations of claims 3-4; Col. 11, line 41) as well as colloidal silicon dioxide and magnesium stearate (meeting the limitations of claims 8 and 9; Col.8, lines 4-5). Enteric polymers are present, including methacrylic acid copolymer (meeting the limitations of claims 1, 10-11; Col. 6, lines 28-29) and zein (further meeting the limitation of claim 11; Col. 12, line 22).

Similar to the teachings of Mehta et al. and Mulye, Beimen et al. teach oral dosage delivery systems comprised of a core comprising a therapeutic agent, an enteric polymer coating over said core, a coating of said therapeutic agent over enteric polymer coat and a protective coating (Col. 7, lines 5-19). Beimen et al. teach that the enteric polymer coating may also contain plasticizers and anti-tack agents, similar to the coating of present claims 1, 21 and 22 (Col. 8, lines 8-10). The most preferred enteric coating is Eudragit L30D-55, which is a methacrylic acid copolymer, and is applied as a 45-55 % weight aqueous solution (meeting the limitation of claims 21-22; Col. 9, lines 11-18).

Furthermore, it is obvious to vary and/or optimize the weight of each ingredient in the controlled release formulation, a maximum plasma concentration, and an AUC provided in the composition, according to the guidance provided by Mehta et al. and Mulye, to ensure that the proper amount of drug is released at the designated time interval. It is noted that "[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955).

Accordingly, it would have been obvious to one having ordinary skill in the art at the time the invention was made to combine the teachings of Mehta et al, which teach a composition for the improved dosing of methylphenidate, with Mulye and Beiman et al., which teach a controlled release pharmaceutical composition that comprises an enteric polymer that aids in delayed release of the drug. One having ordinary skill in the art would have been motivated to combine the teachings of Mehta et al. with Mulye and

Art Unit: 1617

Beiman et al. to formulate a controlled release composition of methylphenidate to reduce abuse potential and for better patient compliance to treat nervous system disorders (as taught by Mehta et al.; Col. 1, lines 26-32).

***Conclusion***

No claims are allowed.

***Contact Information***

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Renee Claytor whose telephone number is 571-272-8394. The examiner can normally be reached on M-F 8:00-4:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan can be reached on 571-272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1617

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Renee Claytor



SREENI PADMANABHAN  
SUPERVISORY PATENT EXAMINER